These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26655732)

  • 1. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.
    Durgam S; Litman RE; Papadakis K; Li D; Németh G; Laszlovszky I
    Int Clin Psychopharmacol; 2016 Mar; 31(2):61-8. PubMed ID: 26655732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.
    Durgam S; Cutler AJ; Lu K; Migliore R; Ruth A; Laszlovszky I; Németh G; Meltzer HY
    J Clin Psychiatry; 2015 Dec; 76(12):e1574-82. PubMed ID: 26717533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.
    Sachs GS; Greenberg WM; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
    J Affect Disord; 2015 Mar; 174():296-302. PubMed ID: 25532076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
    Kane JM; Zukin S; Wang Y; Lu K; Ruth A; Nagy K; Laszlovszky I; Durgam S
    J Clin Psychopharmacol; 2015 Aug; 35(4):367-73. PubMed ID: 26075487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
    Casey DE; Sands EE; Heisterberg J; Yang HM
    Psychopharmacology (Berl); 2008 Oct; 200(3):317-31. PubMed ID: 18597078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
    Németh G; Laszlovszky I; Czobor P; Szalai E; Szatmári B; Harsányi J; Barabássy Á; Debelle M; Durgam S; Bitter I; Marder S; Fleischhacker WW
    Lancet; 2017 Mar; 389(10074):1103-1113. PubMed ID: 28185672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
    Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
    Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.
    Durgam S; Earley W; Lipschitz A; Guo H; Laszlovszky I; Németh G; Vieta E; Calabrese JR; Yatham LN
    Am J Psychiatry; 2016 Mar; 173(3):271-81. PubMed ID: 26541814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Durgam S; Earley W; Li R; Li D; Lu K; Laszlovszky I; Fleischhacker WW; Nasrallah HA
    Schizophr Res; 2016 Oct; 176(2-3):264-271. PubMed ID: 27427558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Fava M; Durgam S; Earley W; Lu K; Hayes R; Laszlovszky I; Németh G
    Int Clin Psychopharmacol; 2018 Nov; 33(6):312-321. PubMed ID: 30045066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.